New MaterniT specimen collection kit
Introducing the upgraded MaterniT specimen collection kit, featuring new branding for better kit identification and fewer components – including one 10 mL Streck tube instead of two – for improved ease-of-use.
Different NIPTs for different patient needs
No other genetic testing laboratory currently offers as much expertise, experience, and choice in NIPT—noninvasive prenatal testing, also called NIPS or cfDNA (cell-free DNA) screening.
With the 2016 acquisition of Sequenom, creator of the first commercially available NIPT, Integrated Genetics now offers three NIPTs—with more than 1 million tests run in total.
Each NIPT offers different capabilities and/or panels to suit the specific needs of your patients and your practice.
MaterniT® GENOME
The only clinically validated genome-wide NIPT, screens all 23 chromosome pairs, reporting aneuploidies, large deletions and duplications greater than 7 Mb in addition to select microdeletions; after more than 35,000 tests resulted, more than 29% of all positive findings were only detectable using genome-wide cfDNA, the methodology used by MaterniT GENOME, as compared to traditional NIPT.1
MaterniT® 21 PLUS
The pioneering NIPT with more than 750,000 tests run; screens the core trisomies 21, 18, and 13, and (optionally) fetal sex, clinically relevant microdeletions, sex chromosome aneuploidies, and trisomies 16 and 22.
informaSeq®
Effective September 27, 2019, Integrated Genetics will no longer offer InformaSeq NIPT. Please contact Client Services at 877-821-7266 or your local sales representative regarding your NIPT screening needs.
| MaterniT® GENOME | MaterniT® 21 PLUS | informaSeq® | ||||
| Detects trisomy 21 (Down syndrome) | ||||||
| Detects trisomy 18 (Edwards syndrome) | ||||||
| Detects trisomy 13 (Patau syndrome) | ||||||
| Detects sex chromosome abnormalities* | ||||||
| Reports fetal fraction | ||||||
| Reports fetal sex* | ||||||
| Multiple gestations† | ||||||
| Detects additional trisomies 22, 16* | ||||||
| Detects select microdeletions, such as 22q11.2 (DiGeorge syndrome)** | ||||||
| Performed as early as 9 weeks | ||||||
| ~5 calendar day turnaround time | ||||||
| Genome-wide analysis of all chromosomes | ||||||
| Reports on any trisomy or monosomy | ||||||
| Detects subchromosomal abnormalities ≥ 7 Mb | ||||||
MaterniT 21 PLUS, MaterniT GENOME, and informaSeq are laboratory-developed test developed and performed exclusively by Integrated Genetics.
* Optional reporting † informaSeq is validated for singleton and twin pregnancies ** Optional reporting for MaterniT 21 PLUS
References
- Ehrich M, Tynan J, Mazloom A, Almasri E, McCullough R, Boomer T, et al. Genome-wide cfDNA screening: clinical laboratory experience with the first 10,000 cases. Genet Med. 2017 Jun 15. 1-6.